Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea.
- Author:
Hae Su KIM
1
;
Hee Jin KIM
;
Sun Hee KIM
;
Joon Young CHOI
;
Young Hyeh KO
;
Won Seog KIM
;
Chul Won JUNG
;
Seok Jin KIM
Author Information
- Publication Type:Original Article
- Keywords: Blastic plasmacytoid dendritic cell neoplasm; Therapeutics; Survival outcome
- MeSH: Bone Marrow; Cyclophosphamide; Daunorubicin; Dendritic Cells*; Dexamethasone; Diagnosis; Disease-Free Survival; Doxorubicin; Drug Therapy; Hematologic Neoplasms; Humans; Korea*; Liver; Lymph Nodes; Male; Methotrexate; Methylprednisolone; Prognosis; Rare Diseases; Retrospective Studies; Skin; Skin Manifestations; Spleen; Vincristine
- From:The Korean Journal of Internal Medicine 2017;32(5):890-899
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that typically presents in the form of skin manifestations with or without lymph node and bone marrow involvement. Given its rarity and recent recognition as a distinct pathological entity, no standard of treatment exists for this aggressive disease and its prognosis is particularly dismal. METHODS: We retrospectively analyzed clinical features and treatment outcomes of patients who were diagnosed with BPDCN between 2000 and 2014. RESULTS: Ten patients had a median age at diagnosis of 41 years (range, 18 to 79), and seven patients were male. Sites of disease involvement were the skin (n = 7), lymph node (n = 5), bone marrow (n = 2), liver (n = 2), spleen (n = 2), and soft tissue (n = 1). Intensified chemotherapy regimens such as hyperCVAD regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), and VPDL (vincristine, methylprednisolone, daunorubicin, L-asparaginase) were used as a first-line treatment. Although all patients treated with intensified chemotherapy showed an objective response (five patients with complete response) with median progression-free survival of 11.2 months (range 6.2 to 19.4), complete remission was not sustained for more than 2 years in any case. The response was relatively long-lived compared with previously reported CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, but the above regimens do not result in long-term remission. CONCLUSIONS: All patients treated with hyperCVAD or VPDL showed an objective response, but the duration of response was relatively short. Thus, the development of more effective induction as well as consolidation treatment strategy should be warranted to improve this rare disease entity.
